Radek Neuwirth

Radek Neuwirth

Auto-generated profile, based on publicly available information

Radek Neuwirth

Masaryk University Medical School , Brno, Czech Republic

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2022 in EP Europace
Verified
Journal Article
Closed access
JHJana Haskova
Jana Haskova
KJKristina Jedlickova
Kristina Jedlickova
JCJakub Cvek
Jakub Cvek
LKLukas Knybel
Lukas Knybel
RNRadek Neuwirth
Radek Neuwirth
JKJosef Kautzner
Josef Kautzner

31 August 2021 in European Heart Journal - Case Reports
Verified
Journal Article
Open access
PDF file
MHMiroslav Hudec
Miroslav Hudec
OJOtakar Jiravsky
Otakar Jiravsky
RSRadim Spacek
Radim Spacek
RNRadek Neuwirth
Radek Neuwirth
LKLukas Knybel
Lukas Knybel
RMRoman Miklik
Roman Miklik
Background: Refractory angina pectoris (AP) significantly impairs quality of life in patients with chronic coronary syndrome. Several minimally invasive methods (coronary sinus reducer, cell therapy, laser or shockwave revascularization, and spinal cord stimulation) or non-invasive methods (external counterpulzation) have been studied. However, their routine clinical use has not been widely implemented. Surgical or endoscopic sympathectomy is feasible for permanently relieving angina, but is often contraindicated due to the extent of complications associated with it. Neuromodulation by anaesthetic blockade of the left-sided stellate ganglion (SG) has been shown to relieve angina for days or weeks. To provide a long-term anti-anginal effect, novel pharmacological (phenol-based) or radiofrequency ablation techniques have been individually used to permanently destroy sympathetic pathways. Case summary: We describe a first-in-man use of stereotactic radiosurgical SG ablation using a linear accelerator (CyberKnife) in a heart failure patient after myocardial infarction with chronic refractory AP. Repeated anaesthetic SG blockade in this patient resulted in a significant, but only short-term, clinical improvement. The left, and subsequently the right, SG was ablated by targeted irradiation. During the 1-year follow-up, the patient remained without angina. We did not observe any clinically relevant early or late complications. Atrial fibrillation that developed 2 months after the second procedure was deemed to be associated with a natural progression of co-existing heart failure. Discussion: We conclude that stereotactic radiosurgical SG ablation has the potential to become a minimally invasive and low-risk procedure to treat refractory angina patients. However, this procedure needs to be evaluated in larger patient populations.

1 October 2019 in European Heart Journal
Verified
Journal Article
Closed access
PDF file
JCJ Cvek
J Cvek
LKL Knybel
L Knybel
RNR Neuwirth
R Neuwirth
OJOtakar Jiravsky
Otakar Jiravsky
MSM Sramko
M Sramko
JKJ Kautzner
J Kautzner
Background: Contemporary stereotactic body radiotherapy (SBRT) enables to accurately concentrate high radiation doses to small volumes of myocardial tissue. There is a rising interest in using SBRT to modify arrhythmogenic substrate in patients with previously failed radiofrequency catheter ablation. However, data on the safety of SBRT for the treatment of VT are lacking. Purpose: This study evaluated the long-term safety of SBRT for the treatment of VT. Methods: SBRT was performed in patients with structural heart disease and failed catheter ablation for VT. The critical part of the VT substrate was identified by electroanatomic mapping (EAM) using a combination of voltage mapping, pace mapping, and activation mapping; and it was marked on a contrast-enhanced computer tomography study as a target for radioablation. SBRT was performed using a radiosurgery system with real-time motion tracking using the tip of the electrode of an indwelling defibrillator as a fiducial marker. A total radiation dose of 25 Gy was delivered to the ablation target in a single session during free breathing. Radiation-induced toxicity was evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Results: Between 2014 and 2018, 18 patients from two electrophysiology centres underwent SBRT for recurrent, drug-resistant VT after previously failed catheter ablation (17 male, 1 female; mean age 63±9 years; 14 ischemic cardiopathy, 3 dilated cardiopathy, 1 fibroma). The mean volume of the ablation target was 34±17 ml, and the mean duration of the therapy was 78±14 minutes. No patient exhibited acute (up to 3 months) elevation of troponin, pericardial effusion, or a decrease in left ventricular ejection fraction from baseline. Four patients developed acute mild nausea, which waned after antiemetic drugs. Two patients gradually developed significant progression of mitral regurgitation after SBRT. One of the patients was treated medically (grade 3 toxicity), but the other had to undergo mitral valve replacement (grade 4 toxicity). No other cardiac or pulmonary radiation related toxicity was observed during a median follow-up of 23 months. Three patients died at 54, 43, and 18 month after SBRT. None of the deaths was related to VT recurrence or complication of SBRT. CARTO, Radiation dose and Survival Conclusions: This is the largest series of patients who underwent EAM-guided SBRT for VT as a bailout therapy after previously failed radiofrequency catheter ablation. Our preliminary data indicate the feasibility and safety of the procedure. To further investigate long-term safety and efficacy of SBRT for VT, we initiated a prospective multicentric study (NCT03819504). Acknowledgement/Funding: Supported by RVO-FNOs/2014

1 March 2018 in EP Europace
Verified
Journal Article
Closed access
PDF file
MFM Fiala
M Fiala
VBV Bulkova
V Bulkova
LRL Rybka
L Rybka
JCJ Chovancik
J Chovancik
RNR Neuwirth
R Neuwirth
JSJ Spinar
J Spinar
Purpose: Single center retrospective analysis of complications of catheter ablation for paroxysmal atrial fibrillation (PAF).